Abstract: A chimeric antigen receptor for recognizing an Fc fragment and an application thereof. The chimeric antigen receptor comprises an antigen binding domain, a transmembrane domain, and an intracellular costimulatory signal transduction domain. The antigen binding domain comprises an Fc? receptor extracellular domain. According to the present invention, the Fc? receptor extracellular domain is used as the antigen binding domain of the chimeric antigen receptor, so that the prepared CAR-T cell can recognize the Fc fragment of an antibody, and achieve, when used in combination with a tumor therapeutic antibody containing an IgG1 or IgG3 Fc fragment, an ADCC effect similar to that of natural immune cells such as NK cells; even in the case that antigen loss occurs in tumor cells, the CAR-T can also be used in combination with an antibody for recognizing another target to achieve an efficient killing effect on the tumor cells.

Abstract: Provided are a genetically modified immune cell, a preparation method therefor, and an application. The immune cell overexpresses HIL-6 and/or L-GP130. HIL-6 or L-GP130 continuous overexpression/conditionally induced overexpression in the immune cell reduces the side effects of CAR-T therapy while maintaining immune and anti-tumour effects, and has potential value in the treatment of malignant tumours and AIDS.

Abstract: The present invention relates to a chimeric antigen receptor, a nucleic acid encoding the same and a cell expressing the same, and their use in manufacturing drugs for treating tumors. The chimeric antigen receptor of the present invention is characterized by its intracellular domain including at least Toll-like receptor 1 and/or Toll-like receptor 2 intracellular domain(s); compared to the prior art, the chimeric antigen receptors of the present invention has significant advantages in T cell expansion, cytotoxicity, T cell invasion and migration, eliminating immunosuppressive effect of regulatory T cells and promoting the formation of memory T cells, etc.